The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Dextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Abstract
A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15- to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulant-dependence treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among homeless and unstably housed women in San Francisco, 47% reported use of cocaine or methamphetamine in the past 6 months, and 14% of those who did not use stimulants at baseline initiated stimulant use within 6 months.231”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [231]
In the citing paper
“Dextroamphetamine causes release of DA (as well as norepinephrine and serotonin) and is an effective treatment for amphetamine abuse [181].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [181]
Citations
Cites
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
Desipramine Facilitation of Initial Cocaine Abstinence
Gawin, F. H. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810020019004 · Cited by 361
Replacement Medication for Cocaine Dependence
Grabowski, J. G., Roache, J. D., Schmitz, J. M., Rhoades, H. M., Creson, D. L., & Korszun, A. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199712000-00008 · Cited by 191
Self-citationGrabowski, J. G., Rhoades, H. M., Elk, R., Schmitz, J. M., Davis, C., Creson, D., & Kirby, K. C. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00004 · Cited by 155
Self-citationDesipramine Treatment of Cocaine Dependence in Methadone-Maintained Patients
Arndt, I. O. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110052008 · Cited by 139
Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency.
Rhoades, H. M., Creson, D. L., Elk, R., Schmitz, J. M., & Grabowski, J. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.1.34 · Cited by 129
Self-citationMethylphenidate Treatment of Cocaine Abusers without Attention Deficit Disorder: A Negative Report
Gawin, F. H., Riordan, C. E., & Kleber, H. D. (1985) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998509016861 · Cited by 120
Methylphenidate (Ritalin®) treatment of cocaine dependence—A preliminary report
Khantzian, E. J., Gawin, F. H., Kleber, H. D., & Riordan, C. E. (1984) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(84)90033-3 · Cited by 120
Levin, F., & Kleber, H. (1995) · Harvard Review of Psychiatry · doi:10.3109/10673229509017144 · Cited by 114
Fluoxetine for Cocaine Dependence in Methadone
Batki, S. L., Manfredi, L., Jacob, P., & Jones, R. T. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199308000-00003 · Cited by 105
Research works printed but not linked: 1
- Batki, 1992, J Clin Psychopharmacol, 13, 243
Cited by
Sorted by citations
Items 201–245 of 245
Ivanov, I., Newcorn, J. H., Morton, K., & Tricamo, M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1268-8_7 · Cited by 4
“This last notion is supported by reports documenting successful treatment of cocaine addiction by the use of therapeutic doses of stimulants (Grabowski et al. 2001; Dackis et al. 2005; Moeller et al. 2008; Anderson et al. 2009; Mooney et al. 2009).”
BackgroundPhenylpropanolamine and the hemorrhagic stroke: A new search for the culprit
Yakoot, M. (2012) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.92491 · Cited by 4
“Being an easy to buy OTC adrenergic agonist that shares many neurochemical properties with cocaine,[11,12] PPA, especially in monocomponent appetite suppressants (unlike the multicomponent cold mixtures), could have been preferably used by patients as an agonist substitution/replacement for withdrawal symptoms or crav…”
BackgroundSotomayor‐Zárate, R., Jara, P., Araos, P. A., Vinet, R., Quiroz, G., Renard, G. M., Espinosa, P., Hurtado‐Guzmán, C., Moya, P. R., Iturriaga‐Vásquez, P., et al. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12168 · Cited by 4
The biogenic amine transporter activity of vinylogous amphetamine analogs
Decker, A. M., Partilla, J. S., Baumann, M. H., Rothman, R. B., & Blough, B. E. (2016) · MedChemComm · doi:10.1039/c6md00245e · Cited by 4
Dopamine “Ups and Downs” in Addiction RevisitedPreprint
Samaha, A., Khoo, S. Y., Ferrario, C. R., & Robinson, T. E. (2020) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/8vch5 · Cited by 4
Herbrink, M., Nuijten, M., Nuijen, B., Huitema, A., Beijnen, J., Hendriks, V., Blanken, P., Janmohamed, A., & van den Brink, W. J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000862 · Cited by 2
Role of stimulant replacement therapy in treating stimulant use disorders
Mak, W., Webb, D., Sutherland, C., & Hirsh, A. (2022) · Canadian Family Physician Médecin de famille canadien · doi:10.46747/cfp.6802109 · Cited by 2
Small, C., Cheng, M. H., Belay, S. S., Bulloch, S. L., Zimmerman, B., Sorkin, A. D., & Block, E. R. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001573 · Cited by 3
“…as phenethylamines are used to treat ADHD as well as substance use disorder (e.g. bupropion for cigarette smoking cessation and prevention of cocaine relapse) (Grabowski et al., 2001; Shearer and Gowing, 2004; Rothman, 2005; Shearer et al., 2009; Lee et al., 2018; Buchholz and Saxon, 2019).”
BackgroundMedications development for food-based and drug use disorders
de Moura, F. B., Kohut, S. J., & Bergman, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.005 · Cited by 2
Medication Strategies for the Management of Cocaine Use Disorder
Kohut, S. J., & Bergman, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803750-8.00063-4 · Cited by 5
Levin, F., Mariani, J., Bisaga, A., & Nunes, E. (2015) · Addiction · doi:10.1111/add.12885 · Cited by 3
“This is consistent with clinical trials in cocaine-dependent patients in whom higher doses of amphetamine were more likely to elicit cocaine abstinence than lower doses or placebo [8,9].”
ResultRough, M. I., Roberts, B. F., & Nader, M. A. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174113 · Cited by 2
Turpin, M. A. C., Rowland, K. C., Anugwom, C., Arocha, M., Carona, A., Gonzalez, B. I., Iskander, G., Snyder, S., Wilson, K., Kaye, A. D., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-98814-8.00027-5 · Cited by 3
Sinatora, A. B., Chiloff, D., Santos, J. P. M., Xu, K. Y., Tardelli, V., & Fidalgo, T. (2025) · Substance use & addiction journal · doi:10.1177/29767342251326374 · Cited by 3
Agonist treatment for stimulant abuse and dependence
Herin, D., & Grabowski, J. (2007) · Elsevier eBooks · doi:10.1016/b978-008044927-2/50057-2 · Cited by 2
Self-citationL'addiction à la cocaïne : de l'épidémiologie aux approches thérapeutiques
Karila, L., Lafaye, G., & Reynaud, M. (2009) · L information psychiatrique · doi:10.1684/ipe.2009.0521 · Cited by 1
“Selon la même approche thérapeutique que dans l ’ addiction aux opiacés ou au tabac, différents agents phar-macologiques comme le méthylphénidate LP [38] chez les dépendants à la cocaïne ayant un trouble hyperactif avec déficit de l ’ attention, ou la d-amphétamine [39-41] ont été testés.”
Carroll, F. I., Kosten, T. R., Buda, J. J., Wang, L., & Walters, B. B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00712 · Cited by 2
“Recent studies of oral amphetamine, which has a faster onset than RTI-336 but shares the same type of extended duration, have been promising in cocaine use disorder patients both with and without adult attention deficit hyperactivity disorder (Grabowski et al., 2001; Levin et al., 2015).”
BackgroundThe scientific basis for the prevention and treatment of substance misuse
Saunders, J. B., & Brady, K. T. (2002) · Current Opinion in Psychiatry · doi:10.1097/00001504-200205000-00001 · Cited by 2
Robinson, H. L., & Banks, M. L. (2026) · ASPET Discovery · doi:10.1016/j.aspetd.2026.100020 · Cited by 1
Neurobiology of Cocaine Dependence Limits Development of Pharmacologic Treatments
Dackis, C. A., & O’Brien, C. P. (2003) · Psychiatric Annals · doi:10.3928/0048-5713-20030901-07 · Cited by 1
Neurochemical Imaging in Addiction
Wai, J. M., LEVIN, F. R., & Martínez, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00001-8 · Cited by 1
Sevarino, K. A., & Shelby, B. C. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch80 · Cited by 1
Myles, J. (2002) · Evidence-Based Mental Health · doi:10.1136/ebmh.5.2.47
REINFORCING, SUBJECTIVE, AND COGNITIVE EFFECTS OF METHAMPHETAMINE DURING D- AMPHETAMINE MAINTENANCE
Pike, E. (2013) · UKnowledge (University of Kentucky)
Treatment of stimulant dependence
Sofuoglu, M., Agath, K., & Kosten, T. R. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544392.021
Nuijten, M., Blanken, P., van de Wetering, B. V. D., Nuijen, B., van den Brink, W. J., & Hendriks, V. (2016) · Verslaving · doi:10.1007/s12501-016-0075-9
Nuijten, M. (2017) · Data Archiving and Networked Services (DANS)
Characterization and Engineering of Human Proteins as Therapeutic Candidates
Kim, K. (2018) · UKnowledge (University of Kentucky) · doi:10.13023/etd.2018.354
Betterton, J., & Birtwistle, M. (2004)
Laqueille, X., Dervaux, A., Omari, F. E., Kanit, M., & Bayle, F. (2006) · European psychiatry (Ed Española) · doi:10.1017/s1134066500002939
La dipendenza da cocaina: verso un'integrazione delle cure
Radolovic, D. (2021) · PNEI REVIEW · doi:10.3280/pnei2021-001004
Clauss, N. J., & Daws, L. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00172-9
(2002) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.356
Environmental influence on the preclinical evaluation of substance use disorder therapeutics
Banks, M. L. (2022) · Advances in pharmacology · doi:10.1016/bs.apha.2021.10.004
L'addiction à la cocaïne : de l'épidémiologie aux approches thérapeutiques
Karila, L., Lafaye, G., & Reynaud, M. (2009) · L information psychiatrique · doi:10.3917/inpsy.8507.0647
Marie, N., & Noble, F. (2024) · Psychotropes · doi:10.3917/psyt.294.0105
Reinforcing Effects of the Novel Dopamine Transport Inhibitors Jjc8-088 and Jjc8-091 in MonkeysPreprint
Allen, M. I., Rahimi, O., Johnson, B., Cao, J., Newman, A. H., & Nader, M. A. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4773961
Chapter 54. Treatment of Substance Use Disorders
Sherman, B. J., Hartwell, K. J., McRae‐Clark, A. L., Herron, A., & Brady, K. T. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as54
Chapter 45. Psychostimulants and Wakefulness-Promoting Agents
DeBattista, C. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as45
Paterson, C., Parkhouse, T., Burke, C., Halicka, M., Palmer, J. C., Gabr, H., Wilson, R., Webster, K. E., Spiga, F., Dawson, S., et al. (2025) · medRxiv · doi:10.64898/2025.12.10.25341965
Improving translational insight using sequential sampling models in drug choice
Cooley, B. J., Millan, E. Z., & McNally, G. P. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07101-z
Paterson, C. A., Parkhouse, T., Burke, C., Halicka, M., Palmer, J. C., Gabr, H., Wilson, R. J., Webster, K. E., Spiga, F., Dawson, S., et al. (2026) · Addiction · doi:10.1111/add.70486
Metadata
- Authors
- Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2001-10
- Volume
- 21
- Issue
- 5
- Pages
- 522-526
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2052304909
- Cited by
- 243
- References
- 22
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 5 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 9 · 2017: 6 · 2016: 14 · 2015: 13 · 2014: 12 · 2013: 11 · 2012: 13
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50da009262-20)
- National Institute on Drug Abuse (DA RO1-6143, DA P50-9262)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- d-amphetamine, cocaine dependence, treatment retention, illicit drug use, dose escalation, urine drug testing, benzoylecgonine, stimulant use disorder, behavior therapy
- MeSH terms
- Adult, Central Nervous System Stimulants, Behavior Therapy, Cocaine, Delayed-Action Preparations, Dextroamphetamine, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Patient Compliance, Patient Dropouts, Severity of Illness Index, Substance Abuse Detection, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
